All News
Damage in Childhood Lupus
d
EurekAlert!
Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise.
Read Article
Is a Biomarker for Adverse Pregnancy Outcomes on the Horizon?
Pregnancy in lupus patients raises concerns due to potential complications like preeclampsia, eclampsia, and increased mortality rates for both mother and baby.
https://t.co/Kv6F21UHze https://t.co/ya8lAkSLC2
Dr. John Cush RheumNow ( View Tweet)
Missed the Live #EULAR2024 #lupus #SLE Topic Recap session yesterday? You can catch up using the link below.
https://t.co/NYJgNb5ME0
@RheumNow @andreafava https://t.co/eeoSux6Csl
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Missed the Live #EULAR2024 #lupus #SLE Topic Recap session yesterday? You can catch up using the link below.
https://t.co/NYJgNb5ME0
@RheumNow @andreafava https://t.co/eeoSux6Csl
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Update on low-dose glucocorticoids in SLE
Glucocorticoids (GC) have been the mainstay of treatment in SLE for nearly three quarters of a century. GC induce a range of anti-inflammatory effects, quickly relieve some symptoms and lower mortality in some life-threatening flares. However, they also have multiple side effects that limit the duration of treatment, as well as the dose used. Accordingly, the 2023 EULAR recommendations for SLE set a target dose of ≤5mg/day. Is low dose GC an achievable target?
Read Article
Voclosporin and Steroids in Lupus Nephritis
Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.
https://t.co/y9QPieV0py https://t.co/GzwntEJLve
Dr. John Cush RheumNow ( View Tweet)
3 Big Lupus Themes from EULAR 2024
Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria, including abstracts POS0732 and OP0255.
https://t.co/XD1EJW2nNE https://t.co/jALVfebb8t
Dr. John Cush RheumNow ( View Tweet)
Belimumab’s Sustained Impact in Lupus
SLE a chronic autoimmune multi-system inflammatory condition, can present with various, sometimes severe, clinical manifestations, leading to high levels of morbidity including impact on quality of life.
https://t.co/4Gf5SJN5FG https://t.co/LxCjLQkaYQ
Dr. John Cush RheumNow ( View Tweet)
Summary of #EULAR2024 #ClinicalPearls
JAKi have expanding disease data
✅ #GCA w #UPA
✅ Awaiting data in #SLE w #UPA & #Deucravacitinib
✅Use in #JIA
✅No new safety signals
@rheumnow
@eular_org
Janet Pope Janetbirdope ( View Tweet)
Does B Cell Depletion Matter?
Dr. Yuz Yusof interviews Dr. Ed Vital regarding abstract OP0077 at Eular 2024 in Vienna, Austria.
https://t.co/IjxGWWjoGD https://t.co/GwLjB4Z7ub
Dr. John Cush RheumNow ( View Tweet)
#EULAR2024 POS1325 Childhood onset #lupus is often more severe with high mortality rate. Similar to findings in adults, 2 cSLE patients with refractory disease including failure to CyC, RTX & PLEX responded to CD19 CAR T cells with similar short term safety profile @RheumNow https://t.co/YD2arjxcso
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS0417 Using EXPLORE Inflammation I & II proteomics, marked immune dysregulation was seen in new ANA+ referral vs HC. 34% progressed to #lupus & #Sjogren. Six potential baseline biomarkers identified & closely resembled established SLE. Validation is ongoing @RheumNow https://t.co/I6HygqNwf7
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 LBA0007 More evidence on deep Bcell depletion in #lupus. Open label trial of Daratumumab, anti-CD38 plasma cell Ab showed rapid reduction in biomarker endpoint, dsDNA, as well as SRI-4 & CLASI-A at Wk12. No SAE but longer F/U needed since IgG reduced by 6g/L @RheumNow https://t.co/IIFPYV9oIr
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Is a Biomarker for Adverse Pregnancy Outcomes on the Horizon?
With a better understanding of pathophysiology, improved management guidelines, available medications, and a multidisciplinary approach, pregnancy for lupus patients has become more feasible. Despite these improvements, some patients still experience poor outcomes, highlighting the need for biomarkers that can predict these risks. An abstract presented at #EULAR2024 (POS1393) explored this possibility.
Read Article
Recommendation for management of fatigue in people with rheumatic disease.
Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it.
I will also add yearly blood work including:
1- VitD
2-HBA1c and LDl
3-TsH. https://t.co/3QvPqMxZSN
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
#EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years.
https://t.co/778buNUq1C https://t.co/4ub8VbrLb6
Dr. John Cush RheumNow ( View Tweet)
#EULAR2024 Please find our Day 1 & Day 2 Recap of selective abstracts/research presented at the conference 😃@RheumNow @DrMiniDey
https://t.co/AHl18gS7gF https://t.co/LEoa9rBNly
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 Please find our Day 1 & Day 2 Recap of selective abstracts/research presented at the conference 😃@RheumNow @DrMiniDey
https://t.co/AHl18gS7gF https://t.co/LEoa9rBNly
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)